Sensei Biotherapeutics Q2 2023 net loss $9.4M; SNS-101 Phase 1/2 enrolling 6 patients

Sensei Biotherapeutics, Inc.

2023-Q2 EPS reported -$0.64

Cash, cash equivalents and marketable securities $78.8M at June 30, 2023, down from $107.1M at Dec 31, 2022; cash runway into H2 2025.
Net loss $9.4M vs $10.5M YoY; R&D expenses $4.8M (down from $6.4M) due to restructuring and lower manufacturing costs.
G&A expenses $5.4M included $1.56M non-recurring stockholder activism costs related to the 2023 annual meeting.
SNS-101 Phase 1/2 enrolled 6 patients across 3 cohorts; combination arm with Libtayo (cemiplimab) expected Q4 2023; PK/safety data by year-end 2023.
Robert Schreiber appointed Chair of Immuno-Oncology Advisory Board; SNS-102 and SNS-103 lead optimization completed, candidate selection expected in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sensei Biotherapeutics, Inc. reported second quarter ended June 30, 2023 results: net income Net loss was $9.4 million.

Period: second quarter ended June 30, 2023
Net income: Net loss was $9.4 million
Result: reported results

Exact text from the filing

Net loss was $9.4 million for the quarter ended June 30, 2023, compared to $10.5 million for the quarter ended June 30, 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Sensei Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-202349

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.